Stay updated on Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial

Sign up to get notified when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the rate of positive sentinel lymph nodes and the effectiveness of pembrolizumab treatment in reducing the rate of positive sentinel lymph nodes in patients with Stage IIB/C melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:11.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that subjects must have clinical stage IIB or IIC resectable melanoma and meet various health and demographic conditions. Previously, no specific information was provided in this section.
    Difference
    53%
    Check dated 2024-05-22T19:54:04.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:23:35.000Z thumbnail image

Stay in the know with updates to Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.